The ability to shift viewpoints and look at things from different angles in the fast-paced world of today is priceless.

🧬✂️Interested in a postdoc on #CRISPR technologies and/or modeling diseases in #Celegans 🏖️ You like Barcelona 👩‍🎓PhD obtained between 01/01/2016 and 31/12/2021 🌍not have resided in Spain for more than 12 months in the last 3 years 📩contact us soon! 👇 agaur.gencat.cat/en/beques-i-aj…

Informativo matinal para ahorrar tiempo 14/02/24

Si me queréis, no dejéis de ver este vídeo… es oro molido. Resume perfectamente lo que pienso y siento. ¡Grande Wyoming! No se podría decir mejor. El Intermedio #AyusoAPrision #ayuso7291

RNA editing is gaining momentum Two RNA-editing therapies for genetic diseases have recently gained approval for clinical trials, raising hopes for safer treatments go.nature.com/4bL9mZM

FDA approves first tumour-infiltrating lymphocyte therapy, bolstering hopes for cell therapies in solid cancers bit.ly/49b0Q4p Iovance’s lifileucel for patients with melanoma is the result of >30 years of research on this cell therapy modality bit.ly/3NldJQE

Excited to share AllofUsResearch program’s flagship genomics paper describing 245,388 clinical-grade genome sequences encompassing >1 billion genetic variants published today in nature nature.com/articles/s4158…

Nature research paper: Genomic data in the All of Us Research Program go.nature.com/49nGFAu

Today we report in Nature Communications the development of laboratory-evolved CBE6 cytosine base editors that offer high on-target C•G-to-T•A editing, virtually no A•T-to-G•C editing, low off-target editing, broad sequence context compatibility, and compatibility with multiple Cas

An exciting new report in Nature Biotechnology from Xiao Wang’s team led by Hongyu Chen shows that mRNAs with branched poly-A tails yield much higher levels, and prolonged production, of the corresponding proteins compared with conventional single-tailed mRNA. This discovery

Johns Hopkins University just released free online courses. No payment is required. Here are 12 courses you can't afford to miss in 2024:

¡Se resistían! Publicados en NEJM los resultados de exa-cel (terapia CRISPR) en #talasemia y #drepanocitosis. 🧐 Eritropatologia_ES EritroEspaña Rare Anemias REHem Spanish Registry Lluis Montoliu nejm.org/doi/full/10.10… nejm.org/doi/full/10.10…

Super excited to see the exa-cel (Casgevy) #SickleCellDisease results out today in NEJM. These are the data that led to FDA approval Dec23 (during #ash2023). Terrific study steering committee. More data to come in younger pts. Now to work on access! Vertex Pharmaceuticals Cancer Center @ CHOP

Gliobastomas are among the most aggressive and fatal cancers. After marked success treating 10 dogs, a unique IV "onionized" mRNA/nanoparticle individualized vaccine induced a striking anti-tumor immune response cell.com/cell/abstract/… Cell FLORIDA

Glad to announce the dosing of the first patient with VERVE-102 in the Heart-2 clinical trial VERVE-102: *in vivo base editor to permanently turn off the PCSK9 gene in liver and durably lower blood LDL-C *delivered using Verve Therapeutics proprietary GalNAc-LNP delivery system as a

"You will only regret in life things you didn't do, not the things you did, event if they did not turn out" Something to apply to science and a scientific career too😉

Today in Science Magazine, together with my former colleagues at NIBR, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. 1/10

Tremendously proud to share my fellowship work, online today in Nature Medicine. We tried to understand why CAR T therapy for AML doesn't work as well as we hoped it would, and how we can solve that. 👇🧵1/10 Penn Medicine CHOP Research Saar Gill nature.com/articles/s4159…

Sammy Basso Sammy Basso, one of the most remarkable people to share our world, passed away last night from complications associated with progeria, the ultra-rare ‘rapid aging’ genetic disease Sammy both suffered from and transcended. Sammy realized that a base editing treatment